51
Participants
Start Date
February 22, 2018
Primary Completion Date
July 25, 2019
Study Completion Date
July 29, 2019
Molidustat (BAY85-3934)
Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
Kainan Hospital, Yatomi
Ehime Prefectural Central Hospital, Matsuyama
Kokura Memorial Hospital, Kitakyushu
JCHO Kyushu Hospital, Kitakyushu
Kurume University Hospital, Kurume
Elm Grove Clinic, Sapporo
Kobe City Medical Center General Hospital, Kobe
Fujisawa City Hospital, Fujisawa
Shonan Kamakura General Hospital, Kamakura
Toranomon Hospital Kajigaya, Kawasaki
Showa University Fujigaoka Hospital, Yokohama
Tohoku Medical and Pharmaceutical University Hospital, Sendai
Niigata Prefectural Shibata Hospital, Shibata
National Hospital Organization Beppu Medical Center, Beppu
Okinawa prefectural Chubu Hospital, Uruma
Fuchu Hospital, Izumi
Fukui-ken Saiseikai Hospital, Fukui
Kyushu University Hospital, Fukuoka
Fukuoka University Hospital, Fukuoka
Japanese Red Cross Fukuoka Hospital, Fukuoka
Fukushima Medical University Hospital, Fukushima
Asahi University Hospital, Gifu
National Hospital Organization Kyoto Medical Center, Kyoto
Nara Prefecture General Medical Center, Nara
Niigata City General Hospital, Niigata
Osaka General Medical Center, Osaka
Japanese Red Cross Oita Hospital, Ōita
Lead Sponsor
Bayer
INDUSTRY